Anti-RANTES antibodies
AssigneeNov Immune S.A.
InventorsNicolas Fischer, Marie Kosco-Vilbois, Francois Mach
Life of this patent
Estimating the term…
Abstract
The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
Claims13
An isolated fully human monoclonal antibody or fragment thereof that binds human Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES), wherein said antibody comprises:
- (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 8;
- (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 9;
- (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 20;
- (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 14;
- (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 15;
- and
- (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 16,
- wherein said antibody binds RANTES.
An isolated fully human monoclonal antibody comprising a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO:
- 18 and a light chain variable sequence comprising the amino acid sequence of SEQ ID NO:
- 4, wherein said antibody binds RANTES.
An isolated antibody that binds human Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES) when human RANTES is bound to a glycosaminoglycan (GAG), wherein said antibody comprises:
- (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 8;
- (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 9;
- (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 20;
- (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 14;
- (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 15;
- and
- (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.